Daniela Michel Diaz-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniela Michel Diaz-González has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Muñoz-Olivos
Faculty of Biotechnology, Popular Autonomous University of the State of Puebla, Puebla City, Mexico
1 shared publication - Elizabeth Bautista-Rodriguez
Faculty of Health Sciences, Universidad Autónoma de Tlaxcala, Tlaxcala, MEX
1 shared publication - Federico Osorio-Antonio
Departamento de Genética Médica, Hospital Infantil de Tlaxcala, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar, Tlaxcala 90606, Mexico
1 shared publication - Francisco Castelán
Departamento de Biología Celular y Fisiología, Unidad Foránea Tlaxcala, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Tlaxcala 90070, México
1 shared publication - Gabriela Elizabeth Campos-Viguri
Center for Research in Applied Science and Advanced Technology, Morelos Unit, National Polytechnic Institute, 62790 Atlacholoaya, Morelos, Mexico
1 shared publication - José Luis Cortez-Sánchez
Environmental Epigenetics and Mental Health Laboratory, Faculty of Chemical Biological Sciences, Autonomous University of Campeche, Campeche, Mexico
1 shared publication
Latest Publications
- 10 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-16
LRG1 in cancer: mechanisms, potential therapeutic target, and use in clinical diagnosis
Leucine-rich alpha-2 glycoprotein 1 (LRG1) is an extracellular protein whose elevated expression has been linked to cancers with poor prognosis and low survival rates. Given its significance as a biomarker, this manuscript explores the role of LRG1 in cancer, as several studies have identified it as a promoter of proliferation, angiogenesis, invasion, and metastasis in breast, ovarian, pancreatic, and neuroblastoma cancers. However, contrasting evidence suggests that LRG1 inhibits proliferation in hepatocellular carcinoma cells and suppresses migration and invasion in esophageal squamous cell carcinoma. We also examine its regulation and the associated signaling pathways, including TGF-β and PI3K/AKT/mTOR.
- 10 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-16
LRG1 in cancer: mechanisms, potential therapeutic target, and use in clinical diagnosis
Leucine-rich alpha-2 glycoprotein 1 (LRG1) is an extracellular protein whose elevated expression has been linked to cancers with poor prognosis and low survival rates. Given its significance as a biomarker, this manuscript explores the role of LRG1 in cancer, as several studies have identified it as a promoter of proliferation, angiogenesis, invasion, and metastasis in breast, ovarian, pancreatic, and neuroblastoma cancers. However, contrasting evidence suggests that LRG1 inhibits proliferation in hepatocellular carcinoma cells and suppresses migration and invasion in esophageal squamous cell carcinoma. We also examine its regulation and the associated signaling pathways, including TGF-β and PI3K/AKT/mTOR.